In a first study published in 2022 they developed a small library of cinnamic acid‐inspired photoswitchable multitarget inhibitors targeting both AChE and monoamine oxidase B (MAO‐B), both implicated in neurodegenerative diseases [64]. This evidence concerns the gene ACHE and neurodegenerative disease.